Tag:

Dyax

Latest Headlines

Latest Headlines

GE Healthcare grabs genomic sequencing CRO SeqWright

GE Healthcare continues its quest to grab more genomic sequencing business, this time by snatching up contract genomic researcher SeqWright.

GE Healthcare ups molecular diagnostics game

GE Healthcare is upping its game in a bid to develop new, targeted molecular diagnostics.

Cubist shelves ecallantide program

Cubist Pharmaceuticals is shelving its program for ecallantide, a once promising therapy for reducing blood loss in surgery, and axing its development deal on the drug with Dyax. The troubled program

Dyax investors bid up shares on FDA's Kalbitor approval

Dyax shares rocketed up 38 percent yesterday evening after the developer announced that the FDA had approved its lead drug Kalbitor (also known as ecallantide or DX-88) for patients with hereditary

Sanofi deal spree creates closer ties with Dyax

Cambridge, MA-based Dyax has grown a lot closer to Sanofi-Aventis in recent weeks. Sanofi-Aventis' previously announced deal to buy Fovea Pharmaceuticals for $540 million has positioned the pharma

Dyax chops 60 jobs after FDA delay

Facing an FDA delay on its lead therapy, Dyax got out the budget-cutting axe and chopped 60 jobs as it scrambled to conserve cash. The layoffs, which will cut more than a third of its staff, should

Dyax shares sink as FDA rejects drug

Shares of Dyax took a beating today as the FDA refused to approve DX-88, the company's treatment for hereditary angioedema (HAE) attacks. HAE is a genetic disease that causes acute episodes of

Biogen, Dyax ink $84M IP deal

Biogen has expanded its IP agreement with Dyax to include the discovery of additional antibody products identified using Dyax's proprietary drug discovery technology, phage display. Under the new

FDA panel narrowly votes in favor of Dyax drug

Dyax has taken a big step toward gaining FDA approval on its first drug. An expert committee narrowly voted to recommend the use of ecallantide-- DX-88--for acute attacks of hereditary angioedema. The

FDA staffers question Dyax studies

Staffers at the FDA have raised questions regarding Dyax's ecallantide, an experimental drug intended to treat hereditary angioedema. In a review, the agency workers said that Dyax's studies did not